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In severe COVID-19, a 5-day remdesivir regimen seems as effective as a 10-day course of treatment 
and it may be safer. To date, the drug has no clearly proven efficacy over time. https://bit.ly/3tKOuvt
Context
Coronavirus disease 2019 (COVID-19), caused by 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection, has caused more than 
96 million cases and over 2 million deaths 
worldwide as of January 21, 2021. As the crisis 
continues, the scientific community, institutions 
and pharmaceutical industries are striving to find 
effective therapies to prevent or treat the disease. 
Remdesivir (GS-5734) was early identified as an 
option.
Remdesivir is an inhibitor of viral RNA 
polymerase. It had previously showed efficacy 
against SARS-CoV-1 and MERS-CoV in vitro. To date, 
three randomised controlled trials [1–3] have been 
published on its use for patients with COVID-19. 
Data from the remdesivir arm of the World Health 
Organization (WHO) Solidarity trial were also made 
available [4].
We provide a commentary on the trial by 
Goldman et al. [3], recently published in the New 
England Journal of Medicine (NEJM) comparing 
a 5- versus 10-day course of treatment with 
remdesivir in severe COVID-19 patients.
Methods
The “Study to Evaluate the Safety and Antiviral 
Activity of Remdesivir (GS-5734) in Participants 
With Severe Coronavirus Disease (COVID-19)” 
was a multicentre, open-label, company-funded, 
randomised phase III clinical trial on the use of 
remdesivir for patients with severe COVID-19, 
defined as patients with confirmed SARS-COV-2 
infection within the 4 days preceding randomisation, 
radiographical evidence of pulmonary involvement 
and receiving supplemental oxygen or having oxygen 
saturation below 94% at room air [3]. Exclusion 
criteria were age <12 years, mechanical ventilation, 
use of extracorporeal membrane oxygenation 
(ECMO), multiorgan failure, liver enzymes levels 
greater than 5-times the normal range, estimated 
creatinine clearance of <50 ml min−1 and concurrent 
experimental treatment for COVID-19.
The patients were randomised to receive 
remdesivir for a total of 5 days or 10 days, with 
a therapeutical scheme of 200 mg intravenous 
remdesivir on day 1, followed by 100 mg for the 
subsequent days, same route. A total of 55 centres 
were involved, distributed among eight countries 
(USA, Italy, Spain, Germany, Hong Kong, Singapore, 
South Korea and Taiwan) from 6 to 26 March 2020.
Journal club
Length of remdesivir treatment 
in patients with severe COVID-19
Cite as: Ippolito M, Cortegiani 
A. Length of remdesivir 
treatment in patients with 
severe COVID-19. Breathe 
2021; 17: 200276.
Commentary on:
Goldman JD, et al. Remdesivir for 5 or 10 Days 
in Patients with Severe Covid-19. N Engl J Med 
2020; 383: 1827–1837.
2 Breathe | 2021 | Volume 17 | No 1
Remdesivir in patients with severe COVID-19
The primary outcome was the score of a seven-
point ordinal scale assessing patients’ clinical 
status, with categories ranging from 1, meaning 
death, and 7, as not hospitalised. Other efficacy 
outcomes were time to clinical improvement, time 
to recovery and time to modified recovery (defined 
as an improvement from a baseline score of 2 to 4 
to a score of 5 to 7 or from a score of 5 to a score 
of 6 or 7), and death for any cause. The secondary 
outcome was the rate of adverse events by 30 days 
after the last dose.
Main results
A total of 397 patients received the treatment after 
randomisation (200 in the 5-day group, 197 in the 
10-day group). Median (interquartile range) time 
of treatment was 5 (5–5) days and 9 (5–10) days 
in the 5- and 10-day groups respectively. The two 
groups were slightly unbalanced in terms of severity 
of disease, with the 10-day group comprising 
more patients starting mechanical ventilation or 
high-flow oxygen therapy (HFOT) before receiving 
the treatment. For efficacy and safety analysis, 
the investigators analysed all patients who were 
randomised and received at least one dose of 
remdesivir. The main results of the study are 
summarised in table 1.
At day 14, clinical improvement, at least 2 points 
in a 7-point ordinal scale, was registered in 64% 
of the patients who had received the treatment for 
5 days, and in 54% of those who had received it for 
10 days. In the adjusted analysis for unbalances 
in baseline clinical status, patients in the 10- and 
5-day course groups had similar distribution in 
clinical status at day 14 (p=0.14). The groups had 
similar outcomes for all the other efficacy endpoints.
The evaluation of safety outcome showed 74% 
(n=145) of patients experiencing adverse events in the 
10-day group, and 70% (n=141) in the 5-day group. 
Serious adverse events were also more frequent in 
the longest course treatment group, compared with 
the shortest course treatment group (35% (n=68) 
versus 21% (n=42)). The most common adverse 
effects in both groups were nausea, acute respiratory 
failure, alanine/aspartate aminotransferase increase, 
constipation and insomnia.
A post hoc analysis was conducted to identify any 
subgroup of patients who may had benefit from 
a long treatment (10-day course). The authors 
reported a lower 14-day mortality rate among those 
who were under mechanical ventilation or ECMO 
at day 5 and assigned to the 10 days treatment 
group versus 5 days (40% (10 out of 25) versus 17% 
(7 out of 41)).
Commentary
The trial failed to demonstrate any significant 
difference between a 5-day versus 10-day treatment 
course with remdesivir in patients with severe 
COVID-19. Patients randomised to receive the 
drug for 10 days had similar or worse outcomes 
compared to a 5-day course of treatment. After a 
protocol amendment, the selected primary endpoint 
of the study changed to clinical status, assessed 
using a 7-point ordinary scale. Indeed, the original 
primary endpoint was normalisation of temperature 
and oxygen saturation through day 14. Despite it is 
reasonable to choose an ordinary scale, as a more 
sensitive measurement for small improvements, 
it is quite atypical to change the primary outcome 
during the study.
The sample size of the trial was correctly 
calculated on the primary outcome (odds ratio 
for improvement of 1.75, power 85%, two-sided 
p=0.05). However, the lack of a control group, e.g. 
with placebo or standard care, is an important 
limitation of this study, since the efficacy of the 
drug cannot be evaluated. The trial was open-
label, potentially introducing performance bias. 
The groups were also unbalanced in terms of 
disease severity, and this can have affected the 
results. Despite randomisation, the 10-day 
treatment group comprised more patients under 
mechanical ventilation or high flow oxygen therapy, 
in comparison with the 5-day group. Furthermore, 
44% of patients in the 10-day cohort did not 
complete the entire 10-day treatment, versus 86% 
in the 5-day cohort. Hospital discharge was the 
most common reason for incomplete treatment, 
and it was more common in the 10-day versus 
5-day group (35% versus 8%). This unbalance 
may be one of the reasons for the different rate 
of side effects, including serious side effects such 
as kidney failure.
In a randomised controlled trial (RCT), no baseline 
differences are expected between patient groups 
and adjustment based on baseline variables should 
be unnecessary. Although the authors did not find 
any significant difference, the use of adjusted 
statistical analysis in an RCT may be considered 
methodologically questionable.
The study was sponsored by Gilead Science 
(Foster City, CA), the manufacturer of the study 
drug, which had role in the study design, data 
collection, trial monitoring, data analysis and 
manuscript draft. However, an independent safety 
monitoring committee reviewed the data after 
study competition for the primary outcome and 
guided the trial flow. Finally, the post hoc analysis 
included patients according to their clinical status 
at day 5, i.e. after having received the treatment for 
5 days. This further limits the validity of the post hoc 
analysis, as during these five days, some patients 
may have worsened their clinical status before 
entering in the analysis. Moreover, the multiplicity 
of the analyses poses the risk of randomly finding 
a positive but unreal result.
It remains difficult to say if the differences 
between the two treatment regimens may be 
related to the study limitations or drug toxicity.
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Implications for practice
The trial suggested that in case of decision to use 
remdesivir in severe COVID-19, a 5-day regimen 
may be as effective as a 10-day course in terms of 
clinical efficacy but safer in terms adverse events. 
This information should be put in context of the 
evidence already available on the drug. The first 
RCT on remdesivir, by Wang et al. [1], had previously 
showed no effect on any clinical or biological 
endpoint (including viral load). Another trial by 
Beigel et al. [2], published in the NEJM in the same 
date of the one by Goldman et al. [3], demonstrated 
a reduction of time to recovery, in comparison with 
placebo (median 10 days versus 15 days; rate ratio 
for recovery 1.29; 95% CI 1.12–1.49; p<0.001), 
suggesting potential benefit for healthcare systems.
The trial came out in a challenging research 
context, with lack of robust evidence to guide 
clinical recommendations and many studies 
published and disseminated despite methodological 
flaws [5–7]. This RCT may be considered a 
questionable allocation of resources. Testing 
different dosing schemes without a control group, 
in the absence of data demonstrating the efficacy 
or the safety of the drug, was probably premature. 
High-quality RCTs, especially those with adaptive 
design, would reasonably provide conclusive data 
on experimental treatments for COVID-19, thus 
limiting overtreatment and “low-value care” [5–7].
The available results from the Solidarity Trial, 
coordinated by the WHO, showed that remdesivir 
may have little or no effect on 28-day mortality or 
in-hospital clinical course of hospitalised patients 
with COVID-19 [4]. In light of the available data, 
WHO issued a conditional recommendation against 
the use of remdesivir in hospitalised patients, 
regardless of disease severity. Currently, there is 
no evidence that remdesivir has effects on survival 
and other outcomes in patients with COVID-19.
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Table 1 Summary of the main results
5-day 10-day
Subjects 200 197
Clinical status of 2–3 points at baseline 53 (26) 69 (35)
Clinical improvement at day 14 129 (64) 107 (54)
Any adverse events 141 (70) 145 (74)
Any serious adverse events 42 (21) 68 (35)
Data are presented as n or n (%). The reported numbers per group represent 
the number of patients per outcome. Information from [3].
